(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: December 22, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–336 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Microbiology and Infectious Diseases Research Committee.

Date: February 7–9, 2001.

Open: February 7, 2001, 9 a.m. to 10 a.m..

Agenda: Reports from various Institute staff.

Place: Holiday Inn Georgetown, Mirage II, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

Closed: February 7, 2001, 10 a.m. to adjournment on February 9, 2001.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Georgetown, Mirage II, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

Contact Person: Gary S. Madonna, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Room 2217, 6700–B Rockledge Drive, MSC 7610, Bethesda, MD 20892–7610, 301–496–2550.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 22, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–335 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Medicine; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6). Title 5 U.S.C., as amended. The journals as potential titles to be indexed by the National Library of Medicine and the discussions could disclose confidential trade secrets of commercial property such as patentable material, and personal information concerning individuals associated with the journals as potential titles to be indexed by the National Library of Medicine, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Literature Selection Technical Review Committee.

Date: February 8–9, 2001.

Open: February 8, 2001, 9am to 11am.

Agenda: Administrative Reports and Program Developments.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 8, 2001, 11 am to 5 pm.

Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine.

*Place:*National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 9, 2001, 8:30 am to 2 pm.

Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Contact Person: Sheldon Kotzin, BA, Chief, Bibliographic Services Division, Division of Library Operations, National Library of Medicine, 8600 Rockville Pike, Bldg 38A/ Room 4N419, Bethesda, MD 20894.

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: December 27, 2000.

Anna P. Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–333 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities; Recombinant DNA Research: Action Under the Guidelines

AGENCY: National Institutes of Health (NIH), PHS, DHHS.

ACTION: Notice of Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).

SUMMARY: This notice amends the NIH Guidelines to set forth NIH's policy on in utero gene transfer clinical research. At the present time, there is insufficient basic and preclinical data to justify the conduct of in utero gene transfer clinical research. Before any in utero gene transfer clinical trial could proceed, significant additional preclinical and relevant clinical studies addressing biodistribution, toxicity, and efficiency of vector transduction would be required, as would further deliberations of the ethical issues associated with this research. As new knowledge evolves from basic, preclinical, and relevant clinical research and as the ethical issues are addressed, the NIH would consider in utero gene transfer clinical protocols for review by the Recombinant DNA Advisory Committee (RAC).

FOR FURTHER INFORMATION CONTACT: Background documentation and additional information can be obtained from the Office of Biotechnology Activities (OBA), National Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, Maryland 20892–7010, Phone 301–496–9838, FAX 301–496–9839. The OBA Web site is located at http://www.nih.gov/od/oba/.

Background Information

In September 1998, the NIH RAC discussed two preliminary proposals for human in utero gene transfer and